Genesis Therapeutics Secures $52M Series A to Further Accelerate AI Innovation and to Launch Drug Discovery & Development Pipeline
Genesis Therapeutics Secures $52M Series A to Further Accelerate AI Innovation and to Launch Drug Discovery & Development Pipeline
12/02/20, 11:05 AM
Location
burlingameMoney raised
$52 million
Round Type
series a
Genesis Therapeutics, a company pioneering AI technologies to create medicines for patients with severe and unmet medical needs, has completed its $52M Series A financing round. Rock Springs Capital led the round. Several other investors participated, including funds and accounts advised by T. Rowe Price Associates, Inc., Seed-round lead investor Andreessen Horowitz, Menlo Ventures, and Radical Ventures, whose founders co-founded the world-leading Vector Institute for Artificial Intelligence
Company Info
Company
The Genesis Molecular Ai Platform
Location
burlingame, california, united states
Additional Info
If you’d like to help create innovative technologies and drive the discovery of life-changing medicines, email info@genesistherapeutics.ai